482 related articles for article (PubMed ID: 28372589)
1. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
2. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
3. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.
Duick DS; Klopper JP; Diggans JC; Friedman L; Kennedy GC; Lanman RB; McIver B
Thyroid; 2012 Oct; 22(10):996-1001. PubMed ID: 22873825
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of the performance of the RosettaGX
Walts AE; Sacks WL; Wu HH; Randolph ML; Bose S
Diagn Cytopathol; 2018 Nov; 46(11):901-907. PubMed ID: 30353692
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
6. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
7. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
8. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
Harrison G; Sosa JA; Jiang X
Arch Pathol Lab Med; 2017 Jul; 141(7):985-989. PubMed ID: 28467214
[TBL] [Abstract][Full Text] [Related]
10. The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules.
Jooya A; Saliba J; Blackburn A; Tamilia M; Hier MP; Mlynarek A; Forest VI; Rochon L; Florea A; Wang H; Payne RJ
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):51. PubMed ID: 27756425
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology.
Abeykoon JP; Mueller L; Dong F; Chintakuntlawar AV; Paludo J; Mortada R
Horm Cancer; 2016 Aug; 7(4):272-8. PubMed ID: 27102883
[TBL] [Abstract][Full Text] [Related]
12. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
13. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
14. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
[TBL] [Abstract][Full Text] [Related]
15. Multicenter clinical experience with the Afirma gene expression classifier.
Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
[TBL] [Abstract][Full Text] [Related]
16. The McGill Thyroid Nodule Score's (MTNS+) role in the investigation of thyroid nodules with benign ultrasound guided fine needle aspiration biopsies: a retrospective review.
Khalife S; Bouhabel S; Forest VI; Hier MP; Rochon L; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2016 May; 45(1):29. PubMed ID: 27142264
[TBL] [Abstract][Full Text] [Related]
17. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
18. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
19. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
Wei S; Veloski C; Sharda P; Ehya H
Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
Geng Y; Aguilar-Jakthong JS; Moatamed NA
Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]